



Novel Drug candidates with Direct- and/or Immune-Mediated Anti-tumor Activities

- We have a lead drug conjugate showing high stability, efficacy and safety in preclinical models of Triple-Negative Breast Cancer (TNBC). We are looking forward to perform additional oncology and immuno-oncology studies of our lead drug conjugate alone or in combination with Keytruda on preclinical models of metastatic TNBC, ovarian and endometrial patient-derived tumors as well as PK/biodistribution/toxicology studies in cynomolgus monkey. Our goal is to file an IND application to the FDA and initiate Phase 1/2a clinical trial of the lead drug conjugate as monotherapy or combination therapy with Keytruda on patients with metastatic TNBC, ovarian and endometrial cancers.
- Upon availability of additional funds we plan to test well-designed conjugates delivering immunostimulant drugs to CD₈ T cells and Natural Killer Cells to enhance their anti-tumor activity against solid tumors.